Table 1.
Published Trials of Hyperthermia Combined With Other Therapies.
| Author (Year) | Site | Study Type | Study Design | Patients (N) | Clinical Benefit (%) | P | Local Control | Overall Survival |
|---|---|---|---|---|---|---|---|---|
| Issels et al52 (2010) | Soft tissue sarcoma | Phase III randomized | EIA plus regional HT | 169 | 84.7% | .002 | 66% (4 years) | 59% (4 years) |
| EIA | 172 | 70.6% | 55% (4 years) | 57% (4 years) | ||||
| Klimanov et al57 (2018) | Breast cancer | Retrospective | CT plus RIMH | 53 | 75.5% | — | — | — |
| CT | 50 | 42% | ||||||
| van der Zee et al50 (2000) | Pelvic tumors | Prospective, randomized | RT plus HT | 182 | 55% (CR) | <.001 | 38% (3 years) | 30% (3 years) |
| RT | 176 | 39% (CR) | 26% (3 years) | 24% (3 years) | ||||
| Cervical cancer | RT plus HT | 58 | 83% (CR) | .003 | 61% (3 years) | 51% (3 years) | ||
| RT | 56 | 57% (CR) | 41% (3 years) | 27% (3 years) | ||||
| Huilgol et al71 (2010) | Head and neck (nonmetastatic) | Prospective randomized | EBRT plus HT | 28 | 78.6% (pCR) | <.05 | — | 245 days |
| EBRT | 26 | 42.4% (pCR) | 141 days | |||||
| Wittlinger et al74 (2009) | Bladder cancer (T1,T2) | Phase II trial | RCT plus RHT | 45 | 96% (pCR) | — | 85% (3 years) | 80% (3 years) |
| Schroeder et al75 (2012) | Rectal cancer | Retrospective | RCT plus RHT | 61 | 16.4% (pCR) | — | The rate of sphincter-sparing surgery (low-lying tumors located within 8 cm of the anal verge): 57% in no-HT group vs 35% no-HT group | |
| RCT | 45 | 6.7% (pCR) | ||||||
| Tsuchiya et al83 (2012) | Pancreatic cancer | Phase II study | CT plus HT | 18 | 61.1% | — | — | 33% (1 year), 17.7 m |
| Mittal BB et al87 (1996) | Metastatic colorectal adenocarcinoma | Pilot phase I/II study | 131I anti-CEA RMoAb and hyperthermia | 6 | — | — | — | — |
Abbreviations: EIA, etoposide, ifosfamide, adriamycin; HT, hyperthermia; CT, chemotherapy; RIMH, regional inductive moderate hyperthermia; RT, radiotherapy; EBRT, external beam radiotherapy; pCR, pathological complete response; RCT, radiochemotherapy; RHT, regional deep hyperthermia.